Skip to main content
Equibles
GH logo

GH · Guardant Health, Inc.

Track GH — free

Use GH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$168.52 -2.40 (-1.40%) At close · Aug 27
Market Cap
$22.61B
Shares
134.20M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$168.52 Open$170.94 Day$168.19–173.10 52W close$54.79–170.92 Avg vol 30d2.1M Short int11.2M · 8.3% float · 5.7d Short vol39% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 26, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +46%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 58
      neutral
      MACD trend Positive
      52-week position 98%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +11%
      trailing
      6-month return +85%
      trailing
      YTD return +65%
      this year
      Relative strength +70%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $156 › 200d $115 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +155 funds added
      Insider flow Distributing
      Net -$42.6M over 90 days · 90% sells
      Short interest Falling
      8.34% of float · ▼ -2.0% MoM · 5.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      598 holders — near 3-yr high, broad support
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth +33%
      Y/Y
      EPS growth +7%
      Y/Y
      Free cash flow $-233.1M
      Balance sheet $1.1B
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 59%
      annualized · 1-yr
      Max drawdown −33%
      past year
      ATR 4.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 4
      Latest guidance · from the 8-K filed Jul 30, 2026
      full year 2026
      Full year 2026 revenue Initiated $1.34B – $1.36B
      prior FY $982.02M midpoint +37.5% Y/Y
      Full year 2026 non-GAAP gross margin Non-GAAP Maintained 64% – 65%
      May 7, 2026 64% – 65% changed to Jul 30, 2026 64% – 65%
      Total non-GAAP operating expenses Non-GAAP Raised $1.08B – $1.1B
      May 7, 2026 $1.05B – $1.07B changed to Jul 30, 2026 $1.08B – $1.1B
      Full-year free cash flow burn Maintained $195M – $205M
      Jun 30, 2026 $195M – $205M changed to Jul 30, 2026 $195M – $205M
      Non-GAAP gross margin Non-GAAP Maintained 64% – 65%
      May 7, 2026 64% – 65% changed to Jul 30, 2026 64% – 65%
      2026
      Screening revenue $218M – $230M
      Prior guidance period ended · from the 8-K filed Oct 29, 2025
      Oncology revenue · full year 2025 25%
      Non-GAAP gross margin · full year 2025 64% – 65%
      Guided vs delivered · last 4 settled
      Total revenue full year 2025
      guided $880M – $890M
      $982.02M Beat +11.0%
      Full-year 2024 revenue full year 2024
      guided $655M – $670M
      $739.02M Beat +11.5%
      Revenue full year 2023
      guided $553M – $556M
      $563.95M Beat +1.7%
      Total revenue full year 2022
      guided $440M – $450M
      $449.54M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +46% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      58 Neutral
      MACD trend
      Positive Bullish
      52-week position
      98% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $156 › 200d $115 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +155 funds added
      Insider flow Distributing
      Net -$42.6M over 90 days · 90% sells
      Short interest Falling
      8.34% of float · ▼ -2.0% MoM · 5.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      598 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $55 Now $169 · 98% Range high $171
      vs 200-day avg +46% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP Net cash used in operating activities -$57.78M
      -$11.76M Purchases of property and equipment
      = Free cash flow -$69.54M
      GAAP → non-GAAP reconciliation
      GAAP GAAP net loss -112.08M
      -11.15M Interest income
      +1.35M Interest expense
      +157K Other expense (income), net
      +372K Provision for income taxes
      +9.44M Depreciation and amortization
      +51.87M Stock-based compensation expense and related employer payroll tax payments
      +0K Contingent consideration
      +1.15M Other
      = Adjusted EBITDA -58.89M
      Non-GAAP general and administrative expense non-GAAP $37.04M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP general and administrative expense 57.93M
      -230K Amortization of intangible assets
      -19.51M Stock-based compensation expense and related employer payroll tax payments
      +0K Contingent consideration
      -1.15M Other
      = Non-GAAP general and administrative expense 37.04M
      Non-GAAP gross profit non-GAAP $200.11M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP gross profit 196.75M
      +148K Amortization of intangible assets
      +3.21M Stock-based compensation expense and related employer payroll tax payments
      = Non-GAAP gross profit 200.11M
      Non-GAAP loss from operations non-GAAP -$67.95M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP loss from operations -121.35M
      +378K Amortization of intangible assets
      +51.87M Stock-based compensation expense and related employer payroll tax payments
      +0K Contingent consideration
      +1.15M Other
      = Non-GAAP loss from operations -67.95M
      Non-GAAP net loss non-GAAP -$58.68M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP net loss -112.08M
      +378K Amortization of intangible assets
      +51.87M Stock-based compensation expense and related employer payroll tax payments
      +0K Contingent consideration
      +0K Impairment of non-marketable equity securities
      +0K Gain on extinguishment of convertible notes
      +1.15M Other
      = Non-GAAP net loss -58.68M
      Non-GAAP net loss per share, basic and diluted non-GAAP -$0.45 Three Months Ended March 31, 2026 —
      Non-GAAP research and development expense non-GAAP $76.59M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP research and development expense 91.04M
      -14.45M Stock-based compensation expense and related employer payroll tax payments
      +0K Contingent consideration
      = Non-GAAP research and development expense 76.59M
      Non-GAAP sales and marketing expense non-GAAP $154.43M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP sales and marketing expense 169.13M
      -14.7M Stock-based compensation expense and related employer payroll tax payments
      = Non-GAAP sales and marketing expense 154.43M
      Screening volume 87,000 full year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GH
      Guardant Health, Inc.
      this stock
      		$22.61B +65.0% +32.9% — 8.3%
      TMO
      Thermo Fisher Scientific Inc.
      		 $234.31B +8.8% +14.5% 34.1 1.3%
      DHR
      Danaher Corp /De/
      		 $151.51B -5.8% +8.5% 38.2 1.2%
      NTRA
      Natera, Inc.
      		 $48.75B +47.8% -2.8% — 3.0%
      A
      Agilent Technologies, Inc.
      		 $43.80B +15.9% +6.4% 31.1 1.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      598
      % held
      101.0%
      Net QoQ
      -3.7M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      596
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      11.2M
      Days to cover
      5.7d
      Change
      -224.5K sh
      View
      Short Volume
      Short vol %
      39%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.0K
      Value
      $150.9K
      As of
      Jul 27, 2026
      View
      Off-Exchange
      Off-exchange %
      46.0%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$42.6M
      Buyers / Sellers
      1 / 9
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Sheldon Whitehouse
      Amount
      $1.0K–$15.0K
      Traded
      Nov 21, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $982.0M
      Net income (FY)
      $-416.3M
      EPS diluted
      $-3.32
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $6.3M
      Shares
      37.5K
      Filed
      Aug 21, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 15, 2026
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Latest news
      Guardant Health to Appeal Federal…
      Published
      Aug 24, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      GH +0.4% +10.6% +84.8% +4.0% +65.0%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -0.7% +6.6% +70.1% +0.8% +51.9%
      Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 484 filings 480 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)